Substantiating the concerns about recombinant human activated protein C use in sepsis*
- 1 December 2004
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 32 (12) , 2542-2543
- https://doi.org/10.1097/01.ccm.0000148090.94378.6a
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis*Critical Care Medicine, 2004
- Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysisBMJ, 2004
- Meta-Analysis: The Effect of Steroids on Survival and Shock during Sepsis Depends on the DoseAnnals of Internal Medicine, 2004
- Risk and the Efficacy of Antiinflammatory AgentsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001